AustralieFrV1, PascalFrancis, Corpus, bibRecord, 001274

Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation

Identifieur interne : 001274 ( PascalFrancis/Corpus ); précédent : 001273; suivant : 001275

Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation

Auteurs : J. A. Snowden ; R. Saccardi ; M. Allez ; S. Ardizzone ; R. Arnold ; R. Cervera ; C. Denton ; C. Hawkey ; M. Labopin ; G. Mancardi ; R. Martin ; J. J. Moore ; J. Passweg ; C. Peters ; M. Rabusin ; M. Rovira ; Jm Van Laar ; D. Farge

Source :

Bone marrow transplantation : (Basingstoke) [ 0268-3369 ] ; 2012.

RBID : Pascal:12-0258465

Descripteurs français

Pascal (Inist)
- Maladie autoimmune, Directive européenne, Recommandation, Hématologie, Greffe de cellules souches hématopoïétiques, EBMT.

English descriptors

KwdEn :
- Autoimmune disease, European directive, European group for blood and marrow transplantation, Hematology, Hematopoietic stem cell transplantation, Recommendation.

Abstract

In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune diseases (ADs) were published, while an international coordinated clinical programme was launched. These guidelines provided broad principles for the field over the following decade and were accompanied by comprehensive data collection in the European Group for Blood and Marrow Transplantation (EBMT) AD Registry. Subsequently, retrospective analyses and prospective phase I/II studies generated evidence to support the feasibility, safety and efficacy of HSCT in several types of severe, treatment-resistant ADs, which became the basis for larger-scale phase II and III studies. In parallel, there has also been an era of immense progress in biological therapy in ADs. The aim of this document is to provide revised and updated guidelines for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments. Patient safety considerations are central to guidance on patient selection and HSCT procedural aspects within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and EBMT accredited centres. A need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures, is emphasized.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0268-3369`
A02	`01`			`@0 BMTRE9`
A03		`1`		`@0 Bone marrow transplant. : (Basingstoke)`
A05				`@2 47`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation`
A11	`01`	`1`		`@1 SNOWDEN (J. A.)`
A11	`02`	`1`		`@1 SACCARDI (R.)`
A11	`03`	`1`		`@1 ALLEZ (M.)`
A11	`04`	`1`		`@1 ARDIZZONE (S.)`
A11	`05`	`1`		`@1 ARNOLD (R.)`
A11	`06`	`1`		`@1 CERVERA (R.)`
A11	`07`	`1`		`@1 DENTON (C.)`
A11	`08`	`1`		`@1 HAWKEY (C.)`
A11	`09`	`1`		`@1 LABOPIN (M.)`
A11	`10`	`1`		`@1 MANCARDI (G.)`
A11	`11`	`1`		`@1 MARTIN (R.)`
A11	`12`	`1`		`@1 MOORE (J. J.)`
A11	`13`	`1`		`@1 PASSWEG (J.)`
A11	`14`	`1`		`@1 PETERS (C.)`
A11	`15`	`1`		`@1 RABUSIN (M.)`
A11	`16`	`1`		`@1 ROVIRA (M.)`
A11	`17`	`1`		`@1 LAAR (Jm Van)`
A11	`18`	`1`		`@1 FARGE (D.)`
A14	`01`			`@1 Department of Haematology, Sheffield Teaching Hospitals NHS Trust @2 Sheffield @3 GBR @Z 1 aut.`
A14	`02`			`@1 Department of Oncology, University of Sheffield @2 Sheffield @3 GBR @Z 1 aut.`
A14	`03`			`@1 Department of Haematology, Careggi University Hospital @2 Firenze @3 ITA @Z 2 aut.`
A14	`04`			`@1 Service de Gastroentérologie, INSERM U 662, Hôpital St Louis @2 Paris @3 FRA @Z 3 aut.`
A14	`05`			`@1 Department of Gastroenterology, Sacco University Hospital @2 Milan @3 ITA @Z 4 aut.`
A14	`06`			`@1 Charite Hospital Berlin @2 Berlin @3 DEU @Z 5 aut.`
A14	`07`			`@1 Department of Autoimmune Diseases, Hospital Clinic @2 Barcelona @3 ESP @Z 6 aut.`
A14	`08`			`@1 Centre for Rheumatology, Royal Free and University College Medical School @2 Hampstead, London @3 GBR @Z 7 aut.`
A14	`09`			`@1 Nottingham Digestive Diseases Centre, University of Nottingham @2 Nottingham @3 GBR @Z 8 aut.`
A14	`10`			`@1 Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, AP-HP, UPMC Univ Paris 06 @2 Paris @3 FRA @Z 9 aut.`
A14	`11`			`@1 Department of Neuroscience, Ophthalmology and Genetics, University of Genova @2 Genova @3 ITA @Z 10 aut.`
A14	`12`			`@1 Institute for Neuroimmunology and Clinical MS Research @2 Hamburg @3 DEU @Z 11 aut.`
A14	`13`			`@1 St Vincent's Hospital @2 Sydney, NSW @3 AUS @Z 12 aut.`
A14	`14`			`@1 Universitaetsspital Basel @2 Basel @3 CHE @Z 13 aut.`
A14	`15`			`@1 BMT Unit, St Anna Children's Hospital @2 Vienna @3 AUT @Z 14 aut.`
A14	`16`			`@1 BMT Unit, Department of Pediatrics, Institute of Maternal and Child Health Burlo Garofolo @2 Trieste @3 ITA @Z 15 aut.`
A14	`17`			`@1 SCT Unit, Hematology Department, Hospital Clinic @2 Barcelona @3 ESP @Z 16 aut.`
A14	`18`			`@1 Newcastle University @2 Newcastle-Upon-Tyne @3 GBR @Z 17 aut.`
A14	`19`			`@1 Department of Internal Medicine, INSERM U 796, Hôpital St Louis @2 Paris @3 FRA @Z 18 aut.`
A17	`01`	`1`		`@1 EBMT Autoimmune Disease Working Party (ADWP) and Paediatric Diseases Working Party (PDWP) @3 INC`
A20				`@1 770-790`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 21176 @5 354000509389020030`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 204 ref.`
A47	`01`	`1`		`@0 12-0258465`
A60				`@1 P @3 C`
A61				`@0 A`
A64	`01`	`1`		`@0 Bone marrow transplantation : (Basingstoke)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune diseases (ADs) were published, while an international coordinated clinical programme was launched. These guidelines provided broad principles for the field over the following decade and were accompanied by comprehensive data collection in the European Group for Blood and Marrow Transplantation (EBMT) AD Registry. Subsequently, retrospective analyses and prospective phase I/II studies generated evidence to support the feasibility, safety and efficacy of HSCT in several types of severe, treatment-resistant ADs, which became the basis for larger-scale phase II and III studies. In parallel, there has also been an era of immense progress in biological therapy in ADs. The aim of this document is to provide revised and updated guidelines for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments. Patient safety considerations are central to guidance on patient selection and HSCT procedural aspects within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and EBMT accredited centres. A need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures, is emphasized.
C02	`01`	`X`		`@0 002B27D02`
C03	`01`	`X`	`FRE`	`@0 Maladie autoimmune @5 02`
C03	`01`	`X`	`ENG`	`@0 Autoimmune disease @5 02`
C03	`01`	`X`	`SPA`	`@0 Enfermedad autoinmune @5 02`
C03	`02`	`X`	`FRE`	`@0 Directive européenne @5 03`
C03	`02`	`X`	`ENG`	`@0 European directive @5 03`
C03	`02`	`X`	`SPA`	`@0 Directiva europea @5 03`
C03	`03`	`X`	`FRE`	`@0 Recommandation @5 05`
C03	`03`	`X`	`ENG`	`@0 Recommendation @5 05`
C03	`03`	`X`	`SPA`	`@0 Recomendación @5 05`
C03	`04`	`X`	`FRE`	`@0 Hématologie @5 06`
C03	`04`	`X`	`ENG`	`@0 Hematology @5 06`
C03	`04`	`X`	`SPA`	`@0 Hematología @5 06`
C03	`05`	`X`	`FRE`	`@0 Greffe de cellules souches hématopoïétiques @4 CD @5 96`
C03	`05`	`X`	`ENG`	`@0 Hematopoietic stem cell transplantation @4 CD @5 96`
C03	`05`	`X`	`SPA`	`@0 Injerto de célula primitiva hematopoyética @4 CD @5 96`
C03	`06`	`X`	`FRE`	`@0 EBMT @4 CD @5 97`
C03	`06`	`X`	`ENG`	`@0 European group for blood and marrow transplantation @4 CD @5 97`
C07	`01`	`X`	`FRE`	`@0 Immunopathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Immunopathology @5 37`
C07	`01`	`X`	`SPA`	`@0 Inmunopatología @5 37`
N21				`@1 198`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 12-0258465 INIST
ET :	Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation
AU :	SNOWDEN (J. A.); SACCARDI (R.); ALLEZ (M.); ARDIZZONE (S.); ARNOLD (R.); CERVERA (R.); DENTON (C.); HAWKEY (C.); LABOPIN (M.); MANCARDI (G.); MARTIN (R.); MOORE (J. J.); PASSWEG (J.); PETERS (C.); RABUSIN (M.); ROVIRA (M.); LAAR (Jm Van); FARGE (D.)
AF :	Department of Haematology, Sheffield Teaching Hospitals NHS Trust/Sheffield/Royaume-Uni (1 aut.); Department of Oncology, University of Sheffield/Sheffield/Royaume-Uni (1 aut.); Department of Haematology, Careggi University Hospital/Firenze/Italie (2 aut.); Service de Gastroentérologie, INSERM U 662, Hôpital St Louis/Paris/France (3 aut.); Department of Gastroenterology, Sacco University Hospital/Milan/Italie (4 aut.); Charite Hospital Berlin/Berlin/Allemagne (5 aut.); Department of Autoimmune Diseases, Hospital Clinic/Barcelona/Espagne (6 aut.); Centre for Rheumatology, Royal Free and University College Medical School/Hampstead, London/Royaume-Uni (7 aut.); Nottingham Digestive Diseases Centre, University of Nottingham/Nottingham/Royaume-Uni (8 aut.); Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, AP-HP, UPMC Univ Paris 06/Paris/France (9 aut.); Department of Neuroscience, Ophthalmology and Genetics, University of Genova/Genova/Italie (10 aut.); Institute for Neuroimmunology and Clinical MS Research/Hamburg/Allemagne (11 aut.); St Vincent's Hospital/Sydney, NSW/Australie (12 aut.); Universitaetsspital Basel/Basel/Suisse (13 aut.); BMT Unit, St Anna Children's Hospital/Vienna/Autriche (14 aut.); BMT Unit, Department of Pediatrics, Institute of Maternal and Child Health Burlo Garofolo/Trieste/Italie (15 aut.); SCT Unit, Hematology Department, Hospital Clinic/Barcelona/Espagne (16 aut.); Newcastle University/Newcastle-Upon-Tyne/Royaume-Uni (17 aut.); Department of Internal Medicine, INSERM U 796, Hôpital St Louis/Paris/France (18 aut.)
DT :	Publication en série; Compte-rendu; Niveau analytique
SO :	Bone marrow transplantation : (Basingstoke); ISSN 0268-3369; Coden BMTRE9; Royaume-Uni; Da. 2012; Vol. 47; No. 6; Pp. 770-790; Bibl. 204 ref.
LA :	Anglais
EA :	In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune diseases (ADs) were published, while an international coordinated clinical programme was launched. These guidelines provided broad principles for the field over the following decade and were accompanied by comprehensive data collection in the European Group for Blood and Marrow Transplantation (EBMT) AD Registry. Subsequently, retrospective analyses and prospective phase I/II studies generated evidence to support the feasibility, safety and efficacy of HSCT in several types of severe, treatment-resistant ADs, which became the basis for larger-scale phase II and III studies. In parallel, there has also been an era of immense progress in biological therapy in ADs. The aim of this document is to provide revised and updated guidelines for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments. Patient safety considerations are central to guidance on patient selection and HSCT procedural aspects within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and EBMT accredited centres. A need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures, is emphasized.
CC :	002B27D02
FD :	Maladie autoimmune; Directive européenne; Recommandation; Hématologie; Greffe de cellules souches hématopoïétiques; EBMT
FG :	Immunopathologie
ED :	Autoimmune disease; European directive; Recommendation; Hematology; Hematopoietic stem cell transplantation; European group for blood and marrow transplantation
EG :	Immunopathology
SD :	Enfermedad autoinmune; Directiva europea; Recomendación; Hematología; Injerto de célula primitiva hematopoyética
LO :	INIST-21176.354000509389020030
ID :	12-0258465

Links to Exploration step

Pascal:12-0258465

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation</title>
<author><name sortKey="Snowden, J A" sort="Snowden, J A" uniqKey="Snowden J" first="J. A." last="Snowden">J. A. Snowden</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Haematology, Sheffield Teaching Hospitals NHS Trust</s1>
<s2>Sheffield</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Oncology, University of Sheffield</s1>
<s2>Sheffield</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saccardi, R" sort="Saccardi, R" uniqKey="Saccardi R" first="R." last="Saccardi">R. Saccardi</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Haematology, Careggi University Hospital</s1>
<s2>Firenze</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Allez, M" sort="Allez, M" uniqKey="Allez M" first="M." last="Allez">M. Allez</name>
<affiliation><inist:fA14 i1="04"><s1>Service de Gastroentérologie, INSERM U 662, Hôpital St Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ardizzone, S" sort="Ardizzone, S" uniqKey="Ardizzone S" first="S." last="Ardizzone">S. Ardizzone</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Gastroenterology, Sacco University Hospital</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Arnold, R" sort="Arnold, R" uniqKey="Arnold R" first="R." last="Arnold">R. Arnold</name>
<affiliation><inist:fA14 i1="06"><s1>Charite Hospital Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cervera, R" sort="Cervera, R" uniqKey="Cervera R" first="R." last="Cervera">R. Cervera</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Autoimmune Diseases, Hospital Clinic</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Denton, C" sort="Denton, C" uniqKey="Denton C" first="C." last="Denton">C. Denton</name>
<affiliation><inist:fA14 i1="08"><s1>Centre for Rheumatology, Royal Free and University College Medical School</s1>
<s2>Hampstead, London</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hawkey, C" sort="Hawkey, C" uniqKey="Hawkey C" first="C." last="Hawkey">C. Hawkey</name>
<affiliation><inist:fA14 i1="09"><s1>Nottingham Digestive Diseases Centre, University of Nottingham</s1>
<s2>Nottingham</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Labopin, M" sort="Labopin, M" uniqKey="Labopin M" first="M." last="Labopin">M. Labopin</name>
<affiliation><inist:fA14 i1="10"><s1>Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, AP-HP, UPMC Univ Paris 06</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mancardi, G" sort="Mancardi, G" uniqKey="Mancardi G" first="G." last="Mancardi">G. Mancardi</name>
<affiliation><inist:fA14 i1="11"><s1>Department of Neuroscience, Ophthalmology and Genetics, University of Genova</s1>
<s2>Genova</s2>
<s3>ITA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martin, R" sort="Martin, R" uniqKey="Martin R" first="R." last="Martin">R. Martin</name>
<affiliation><inist:fA14 i1="12"><s1>Institute for Neuroimmunology and Clinical MS Research</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Moore, J J" sort="Moore, J J" uniqKey="Moore J" first="J. J." last="Moore">J. J. Moore</name>
<affiliation><inist:fA14 i1="13"><s1>St Vincent's Hospital</s1>
<s2>Sydney, NSW</s2>
<s3>AUS</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Passweg, J" sort="Passweg, J" uniqKey="Passweg J" first="J." last="Passweg">J. Passweg</name>
<affiliation><inist:fA14 i1="14"><s1>Universitaetsspital Basel</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peters, C" sort="Peters, C" uniqKey="Peters C" first="C." last="Peters">C. Peters</name>
<affiliation><inist:fA14 i1="15"><s1>BMT Unit, St Anna Children's Hospital</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rabusin, M" sort="Rabusin, M" uniqKey="Rabusin M" first="M." last="Rabusin">M. Rabusin</name>
<affiliation><inist:fA14 i1="16"><s1>BMT Unit, Department of Pediatrics, Institute of Maternal and Child Health Burlo Garofolo</s1>
<s2>Trieste</s2>
<s3>ITA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rovira, M" sort="Rovira, M" uniqKey="Rovira M" first="M." last="Rovira">M. Rovira</name>
<affiliation><inist:fA14 i1="17"><s1>SCT Unit, Hematology Department, Hospital Clinic</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Laar, Jm Van" sort="Laar, Jm Van" uniqKey="Laar J" first="Jm Van" last="Laar">Jm Van Laar</name>
<affiliation><inist:fA14 i1="18"><s1>Newcastle University</s1>
<s2>Newcastle-Upon-Tyne</s2>
<s3>GBR</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Farge, D" sort="Farge, D" uniqKey="Farge D" first="D." last="Farge">D. Farge</name>
<affiliation><inist:fA14 i1="19"><s1>Department of Internal Medicine, INSERM U 796, Hôpital St Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0258465</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0258465 INIST</idno>
<idno type="RBID">Pascal:12-0258465</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001274</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation</title>
<author><name sortKey="Snowden, J A" sort="Snowden, J A" uniqKey="Snowden J" first="J. A." last="Snowden">J. A. Snowden</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Haematology, Sheffield Teaching Hospitals NHS Trust</s1>
<s2>Sheffield</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Oncology, University of Sheffield</s1>
<s2>Sheffield</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saccardi, R" sort="Saccardi, R" uniqKey="Saccardi R" first="R." last="Saccardi">R. Saccardi</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Haematology, Careggi University Hospital</s1>
<s2>Firenze</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Allez, M" sort="Allez, M" uniqKey="Allez M" first="M." last="Allez">M. Allez</name>
<affiliation><inist:fA14 i1="04"><s1>Service de Gastroentérologie, INSERM U 662, Hôpital St Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ardizzone, S" sort="Ardizzone, S" uniqKey="Ardizzone S" first="S." last="Ardizzone">S. Ardizzone</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Gastroenterology, Sacco University Hospital</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Arnold, R" sort="Arnold, R" uniqKey="Arnold R" first="R." last="Arnold">R. Arnold</name>
<affiliation><inist:fA14 i1="06"><s1>Charite Hospital Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cervera, R" sort="Cervera, R" uniqKey="Cervera R" first="R." last="Cervera">R. Cervera</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Autoimmune Diseases, Hospital Clinic</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Denton, C" sort="Denton, C" uniqKey="Denton C" first="C." last="Denton">C. Denton</name>
<affiliation><inist:fA14 i1="08"><s1>Centre for Rheumatology, Royal Free and University College Medical School</s1>
<s2>Hampstead, London</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hawkey, C" sort="Hawkey, C" uniqKey="Hawkey C" first="C." last="Hawkey">C. Hawkey</name>
<affiliation><inist:fA14 i1="09"><s1>Nottingham Digestive Diseases Centre, University of Nottingham</s1>
<s2>Nottingham</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Labopin, M" sort="Labopin, M" uniqKey="Labopin M" first="M." last="Labopin">M. Labopin</name>
<affiliation><inist:fA14 i1="10"><s1>Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, AP-HP, UPMC Univ Paris 06</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mancardi, G" sort="Mancardi, G" uniqKey="Mancardi G" first="G." last="Mancardi">G. Mancardi</name>
<affiliation><inist:fA14 i1="11"><s1>Department of Neuroscience, Ophthalmology and Genetics, University of Genova</s1>
<s2>Genova</s2>
<s3>ITA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martin, R" sort="Martin, R" uniqKey="Martin R" first="R." last="Martin">R. Martin</name>
<affiliation><inist:fA14 i1="12"><s1>Institute for Neuroimmunology and Clinical MS Research</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Moore, J J" sort="Moore, J J" uniqKey="Moore J" first="J. J." last="Moore">J. J. Moore</name>
<affiliation><inist:fA14 i1="13"><s1>St Vincent's Hospital</s1>
<s2>Sydney, NSW</s2>
<s3>AUS</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Passweg, J" sort="Passweg, J" uniqKey="Passweg J" first="J." last="Passweg">J. Passweg</name>
<affiliation><inist:fA14 i1="14"><s1>Universitaetsspital Basel</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peters, C" sort="Peters, C" uniqKey="Peters C" first="C." last="Peters">C. Peters</name>
<affiliation><inist:fA14 i1="15"><s1>BMT Unit, St Anna Children's Hospital</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rabusin, M" sort="Rabusin, M" uniqKey="Rabusin M" first="M." last="Rabusin">M. Rabusin</name>
<affiliation><inist:fA14 i1="16"><s1>BMT Unit, Department of Pediatrics, Institute of Maternal and Child Health Burlo Garofolo</s1>
<s2>Trieste</s2>
<s3>ITA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rovira, M" sort="Rovira, M" uniqKey="Rovira M" first="M." last="Rovira">M. Rovira</name>
<affiliation><inist:fA14 i1="17"><s1>SCT Unit, Hematology Department, Hospital Clinic</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Laar, Jm Van" sort="Laar, Jm Van" uniqKey="Laar J" first="Jm Van" last="Laar">Jm Van Laar</name>
<affiliation><inist:fA14 i1="18"><s1>Newcastle University</s1>
<s2>Newcastle-Upon-Tyne</s2>
<s3>GBR</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Farge, D" sort="Farge, D" uniqKey="Farge D" first="D." last="Farge">D. Farge</name>
<affiliation><inist:fA14 i1="19"><s1>Department of Internal Medicine, INSERM U 796, Hôpital St Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Bone marrow transplantation : (Basingstoke)</title>
<title level="j" type="abbreviated">Bone marrow transplant. : (Basingstoke)</title>
<idno type="ISSN">0268-3369</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Bone marrow transplantation : (Basingstoke)</title>
<title level="j" type="abbreviated">Bone marrow transplant. : (Basingstoke)</title>
<idno type="ISSN">0268-3369</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Autoimmune disease</term>
<term>European directive</term>
<term>European group for blood and marrow transplantation</term>
<term>Hematology</term>
<term>Hematopoietic stem cell transplantation</term>
<term>Recommendation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie autoimmune</term>
<term>Directive européenne</term>
<term>Recommandation</term>
<term>Hématologie</term>
<term>Greffe de cellules souches hématopoïétiques</term>
<term>EBMT</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune diseases (ADs) were published, while an international coordinated clinical programme was launched. These guidelines provided broad principles for the field over the following decade and were accompanied by comprehensive data collection in the European Group for Blood and Marrow Transplantation (EBMT) AD Registry. Subsequently, retrospective analyses and prospective phase I/II studies generated evidence to support the feasibility, safety and efficacy of HSCT in several types of severe, treatment-resistant ADs, which became the basis for larger-scale phase II and III studies. In parallel, there has also been an era of immense progress in biological therapy in ADs. The aim of this document is to provide revised and updated guidelines for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments. Patient safety considerations are central to guidance on patient selection and HSCT procedural aspects within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and EBMT accredited centres. A need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures, is emphasized.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0268-3369</s0>
</fA01>
<fA02 i1="01"><s0>BMTRE9</s0>
</fA02>
<fA03 i2="1"><s0>Bone marrow transplant. : (Basingstoke)</s0>
</fA03>
<fA05><s2>47</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SNOWDEN (J. A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SACCARDI (R.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ALLEZ (M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ARDIZZONE (S.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ARNOLD (R.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CERVERA (R.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>DENTON (C.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>HAWKEY (C.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>LABOPIN (M.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MANCARDI (G.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>MARTIN (R.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>MOORE (J. J.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>PASSWEG (J.)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>PETERS (C.)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>RABUSIN (M.)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>ROVIRA (M.)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>LAAR (Jm Van)</s1>
</fA11>
<fA11 i1="18" i2="1"><s1>FARGE (D.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Haematology, Sheffield Teaching Hospitals NHS Trust</s1>
<s2>Sheffield</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Oncology, University of Sheffield</s1>
<s2>Sheffield</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Haematology, Careggi University Hospital</s1>
<s2>Firenze</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Service de Gastroentérologie, INSERM U 662, Hôpital St Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Gastroenterology, Sacco University Hospital</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Charite Hospital Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Autoimmune Diseases, Hospital Clinic</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Centre for Rheumatology, Royal Free and University College Medical School</s1>
<s2>Hampstead, London</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Nottingham Digestive Diseases Centre, University of Nottingham</s1>
<s2>Nottingham</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, AP-HP, UPMC Univ Paris 06</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Department of Neuroscience, Ophthalmology and Genetics, University of Genova</s1>
<s2>Genova</s2>
<s3>ITA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Institute for Neuroimmunology and Clinical MS Research</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>St Vincent's Hospital</s1>
<s2>Sydney, NSW</s2>
<s3>AUS</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Universitaetsspital Basel</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="15"><s1>BMT Unit, St Anna Children's Hospital</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="16"><s1>BMT Unit, Department of Pediatrics, Institute of Maternal and Child Health Burlo Garofolo</s1>
<s2>Trieste</s2>
<s3>ITA</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="17"><s1>SCT Unit, Hematology Department, Hospital Clinic</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="18"><s1>Newcastle University</s1>
<s2>Newcastle-Upon-Tyne</s2>
<s3>GBR</s3>
<sZ>17 aut.</sZ>
</fA14>
<fA14 i1="19"><s1>Department of Internal Medicine, INSERM U 796, Hôpital St Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>18 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>EBMT Autoimmune Disease Working Party (ADWP) and Paediatric Diseases Working Party (PDWP)</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>770-790</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>21176</s2>
<s5>354000509389020030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>204 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0258465</s0>
</fA47>
<fA60><s1>P</s1>
<s3>C</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Bone marrow transplantation : (Basingstoke)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune diseases (ADs) were published, while an international coordinated clinical programme was launched. These guidelines provided broad principles for the field over the following decade and were accompanied by comprehensive data collection in the European Group for Blood and Marrow Transplantation (EBMT) AD Registry. Subsequently, retrospective analyses and prospective phase I/II studies generated evidence to support the feasibility, safety and efficacy of HSCT in several types of severe, treatment-resistant ADs, which became the basis for larger-scale phase II and III studies. In parallel, there has also been an era of immense progress in biological therapy in ADs. The aim of this document is to provide revised and updated guidelines for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments. Patient safety considerations are central to guidance on patient selection and HSCT procedural aspects within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and EBMT accredited centres. A need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures, is emphasized.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B27D02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie autoimmune</s0>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Autoimmune disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Enfermedad autoinmune</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Directive européenne</s0>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>European directive</s0>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Directiva europea</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Recommandation</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Recommendation</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Recomendación</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Hématologie</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Hematology</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hematología</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Greffe de cellules souches hématopoïétiques</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Hematopoietic stem cell transplantation</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Injerto de célula primitiva hematopoyética</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>EBMT</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>European group for blood and marrow transplantation</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Immunopathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Immunopathology</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Inmunopatología</s0>
<s5>37</s5>
</fC07>
<fN21><s1>198</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 12-0258465 INIST</NO>
<ET>Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation</ET>
<AU>SNOWDEN (J. A.); SACCARDI (R.); ALLEZ (M.); ARDIZZONE (S.); ARNOLD (R.); CERVERA (R.); DENTON (C.); HAWKEY (C.); LABOPIN (M.); MANCARDI (G.); MARTIN (R.); MOORE (J. J.); PASSWEG (J.); PETERS (C.); RABUSIN (M.); ROVIRA (M.); LAAR (Jm Van); FARGE (D.)</AU>
<AF>Department of Haematology, Sheffield Teaching Hospitals NHS Trust/Sheffield/Royaume-Uni (1 aut.); Department of Oncology, University of Sheffield/Sheffield/Royaume-Uni (1 aut.); Department of Haematology, Careggi University Hospital/Firenze/Italie (2 aut.); Service de Gastroentérologie, INSERM U 662, Hôpital St Louis/Paris/France (3 aut.); Department of Gastroenterology, Sacco University Hospital/Milan/Italie (4 aut.); Charite Hospital Berlin/Berlin/Allemagne (5 aut.); Department of Autoimmune Diseases, Hospital Clinic/Barcelona/Espagne (6 aut.); Centre for Rheumatology, Royal Free and University College Medical School/Hampstead, London/Royaume-Uni (7 aut.); Nottingham Digestive Diseases Centre, University of Nottingham/Nottingham/Royaume-Uni (8 aut.); Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, AP-HP, UPMC Univ Paris 06/Paris/France (9 aut.); Department of Neuroscience, Ophthalmology and Genetics, University of Genova/Genova/Italie (10 aut.); Institute for Neuroimmunology and Clinical MS Research/Hamburg/Allemagne (11 aut.); St Vincent's Hospital/Sydney, NSW/Australie (12 aut.); Universitaetsspital Basel/Basel/Suisse (13 aut.); BMT Unit, St Anna Children's Hospital/Vienna/Autriche (14 aut.); BMT Unit, Department of Pediatrics, Institute of Maternal and Child Health Burlo Garofolo/Trieste/Italie (15 aut.); SCT Unit, Hematology Department, Hospital Clinic/Barcelona/Espagne (16 aut.); Newcastle University/Newcastle-Upon-Tyne/Royaume-Uni (17 aut.); Department of Internal Medicine, INSERM U 796, Hôpital St Louis/Paris/France (18 aut.)</AF>
<DT>Publication en série; Compte-rendu; Niveau analytique</DT>
<SO>Bone marrow transplantation : (Basingstoke); ISSN 0268-3369; Coden BMTRE9; Royaume-Uni; Da. 2012; Vol. 47; No. 6; Pp. 770-790; Bibl. 204 ref.</SO>
<LA>Anglais</LA>
<EA>In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune diseases (ADs) were published, while an international coordinated clinical programme was launched. These guidelines provided broad principles for the field over the following decade and were accompanied by comprehensive data collection in the European Group for Blood and Marrow Transplantation (EBMT) AD Registry. Subsequently, retrospective analyses and prospective phase I/II studies generated evidence to support the feasibility, safety and efficacy of HSCT in several types of severe, treatment-resistant ADs, which became the basis for larger-scale phase II and III studies. In parallel, there has also been an era of immense progress in biological therapy in ADs. The aim of this document is to provide revised and updated guidelines for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments. Patient safety considerations are central to guidance on patient selection and HSCT procedural aspects within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and EBMT accredited centres. A need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures, is emphasized.</EA>
<CC>002B27D02</CC>
<FD>Maladie autoimmune; Directive européenne; Recommandation; Hématologie; Greffe de cellules souches hématopoïétiques; EBMT</FD>
<FG>Immunopathologie</FG>
<ED>Autoimmune disease; European directive; Recommendation; Hematology; Hematopoietic stem cell transplantation; European group for blood and marrow transplantation</ED>
<EG>Immunopathology</EG>
<SD>Enfermedad autoinmune; Directiva europea; Recomendación; Hematología; Injerto de célula primitiva hematopoyética</SD>
<LO>INIST-21176.354000509389020030</LO>
<ID>12-0258465</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001274 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001274 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:12-0258465
   |texte=   Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation

Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri